2 results
Approved WMOCompleted
Primary* To compare the disease free survival (DFS) in patients with HL after achieving a complete response following AHSCT with HDT who are treated with panobinostat versus those who receive placebo based on investigator*s review of radiological…
Approved WMOCompleted
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…